Unity Biotechnology, Inc.
UBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $236 | $4,784 |
| % Growth | – | -100% | -95.1% | – |
| Cost of Goods Sold | $867 | $19,699 | $2,180 | $2,880 |
| Gross Profit | -$867 | -$19,699 | -$1,944 | $1,904 |
| % Margin | – | – | -823.7% | 39.8% |
| R&D Expenses | $13,006 | $20,799 | $36,859 | $38,393 |
| G&A Expenses | $15,460 | $18,766 | $20,949 | $23,056 |
| SG&A Expenses | $15,460 | $18,766 | $20,949 | $23,056 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$602 | -$14,597 | -$35,459 | -$2,880 |
| Operating Expenses | $27,864 | $24,968 | $22,349 | $58,569 |
| Operating Income | -$31,171 | -$44,667 | -$57,572 | -$56,665 |
| % Margin | – | – | -24,394.9% | -1,184.5% |
| Other Income/Exp. Net | $5,181 | $4,807 | $13,103 | -$4,060 |
| Pre-Tax Income | -$25,990 | -$39,860 | -$44,469 | -$60,725 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25,990 | -$39,860 | -$44,469 | -$60,725 |
| % Margin | – | – | -18,842.8% | -1,269.3% |
| EPS | -1.54 | -2.7 | -4.68 | -10.9 |
| % Growth | 43% | 42.3% | 57.1% | – |
| EPS Diluted | -1.54 | -2.7 | -4.68 | -10.9 |
| Weighted Avg Shares Out | 16,827 | 14,773 | 9,494 | 5,582 |
| Weighted Avg Shares Out Dil | 16,827 | 14,774 | 9,494 | 5,582 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,733 | $422 | $1,220 | $100 |
| Interest Expense | $0 | $0 | $3,558 | $3,177 |
| Depreciation & Amortization | $867 | $1,182 | $2,180 | $2,880 |
| EBITDA | -$25,123 | -$37,283 | -$38,731 | -$54,668 |
| % Margin | – | – | -16,411.4% | -1,142.7% |